awmsg logo



buprenorphine/naloxone (Suboxone®)


Reference No. 70

Publication date:
18/07/2008


Appraisal information

buprenorphine/naloxone (Suboxone®) 8 mg/2 mg sublingual tablet
buprenorphine/naloxone (Suboxone®) 2 mg/0.5 mg sublingual tablet


Company: Merck Sharp & Dohme Ltd
BNF category: Central nervous system
NMG meeting date: 14/05/2008
AWMSG meeting date: 13/06/2008
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1108
Ministerial ratification: 17/07/2008

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Buprenorphine/naloxone (Suboxone®) is recommended for restricted use within NHS Wales as substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. In accordance with NICE guidance such treatment should be considered in patients who are unsuitable for maintenance treatment with methadone.
Final Appraisal Recommendation (FAR)
Download